📊 BCLI Key Takeaways
Is Brainstorm Cell Therapeutics Inc.. (BCLI) a Good Investment?
Brainstorm Cell Therapeutics faces severe financial distress with negative stockholders' equity of -7.7M, liabilities exceeding assets by 7.7x, and no revenue generation. The company is burning cash at an unsustainable rate (-6.2M operating cash flow) with minimal liquidity (5.0K cash) and a critically low current ratio of 0.06x, indicating imminent solvency concerns.
BrainStorm Cell Therapeutics shows extremely weak fundamentals, with no reported revenue, persistent operating and net losses, and deeply negative free cash flow. Financial health appears highly distressed given just $5K of cash, a 0.06x current ratio, and negative stockholders' equity, which raises serious going-concern and funding-risk concerns. While EPS loss improved year over year, that improvement does not offset the company’s severe liquidity constraints and lack of operating scale.
Why Buy Brainstorm Cell Therapeutics Inc.. Stock? BCLI Key Strengths
- Company has not yet filed for bankruptcy, indicating some ongoing operations
- EPS improved 61.5% year-over-year, though still deeply negative
- No long-term debt obligations that could accelerate financial distress
- EPS loss improved meaningfully year over year, indicating some reduction in per-share loss pressure
- Operating cash burn is large but somewhat below reported net loss, suggesting limited non-cash distortion
- Capital expenditure requirements are minimal, which reduces fixed investment burden
BCLI Stock Risks: Brainstorm Cell Therapeutics Inc.. Investment Risks
- Negative stockholders' equity (-7.7M) indicates liabilities exceed assets; company is technically insolvent
- Zero revenue with -7.9M net loss and -6.2M operating cash burn; business model not generating income
- Critical liquidity crisis: only 5.0K cash on hand with 9.1M total liabilities and current ratio of 0.06x
- Negative ROA of -570.5% demonstrates severe asset inefficiency and value destruction
- No insider buying activity in last 90 days suggests lack of management confidence
- Dependency on external financing or capital raises for survival
- No revenue base is reported, making growth quality and business scalability highly uncertain
- Liquidity is critically weak, with only $5K in cash and a 0.06x current and quick ratio
- Negative equity and sustained cash burn indicate elevated balance-sheet stress and dependence on external financing
Key Metrics to Watch
- Cash balance and runway to next financing event
- Quarterly cash burn rate trends and path to profitability/revenue generation
- Changes in stockholders' equity and potential debt restructuring or dilutive equity raises
- Operating cash flow improvements or further deterioration
- Quarterly revenue generation or commercialization progress
- Cash runway and changes in working capital, equity, or new financing obligations
Brainstorm Cell Therapeutics Inc.. (BCLI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BCLI Profit Margin, ROE & Profitability Analysis
BCLI vs Healthcare Sector: How Brainstorm Cell Therapeutics Inc.. Compares
How Brainstorm Cell Therapeutics Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Brainstorm Cell Therapeutics Inc.. Stock Overvalued? BCLI Valuation Analysis 2026
Based on fundamental analysis, Brainstorm Cell Therapeutics Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Brainstorm Cell Therapeutics Inc.. Balance Sheet: BCLI Debt, Cash & Liquidity
BCLI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Brainstorm Cell Therapeutics Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.31 indicates the company is currently unprofitable.
BCLI Revenue Growth, EPS Growth & YoY Performance
Brainstorm Cell Therapeutics Inc.. Dividends, Buybacks & Capital Allocation
BCLI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Brainstorm Cell Therapeutics Inc.. (CIK: 0001137883)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCLI
What is the AI rating for BCLI?
Brainstorm Cell Therapeutics Inc.. (BCLI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCLI's key strengths?
Claude: Company has not yet filed for bankruptcy, indicating some ongoing operations. EPS improved 61.5% year-over-year, though still deeply negative. ChatGPT: EPS loss improved meaningfully year over year, indicating some reduction in per-share loss pressure. Operating cash burn is large but somewhat below reported net loss, suggesting limited non-cash distortion.
What are the risks of investing in BCLI?
Claude: Negative stockholders' equity (-7.7M) indicates liabilities exceed assets; company is technically insolvent. Zero revenue with -7.9M net loss and -6.2M operating cash burn; business model not generating income. ChatGPT: No revenue base is reported, making growth quality and business scalability highly uncertain. Liquidity is critically weak, with only $5K in cash and a 0.06x current and quick ratio.
What is BCLI's revenue and growth?
Brainstorm Cell Therapeutics Inc.. reported revenue of N/A.
Does BCLI pay dividends?
Brainstorm Cell Therapeutics Inc.. does not currently pay dividends.
Where can I find BCLI SEC filings?
Official SEC filings for Brainstorm Cell Therapeutics Inc.. (CIK: 0001137883) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCLI's EPS?
Brainstorm Cell Therapeutics Inc.. has a diluted EPS of $-0.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BCLI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Brainstorm Cell Therapeutics Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BCLI stock overvalued or undervalued?
Valuation metrics for BCLI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BCLI stock in 2026?
Our dual AI analysis gives Brainstorm Cell Therapeutics Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCLI's free cash flow?
Brainstorm Cell Therapeutics Inc..'s operating cash flow is $-6.2M, with capital expenditures of $18.0K.
How does BCLI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.06 (avg: 2).